Angiochem to Present at Stifel Nicolaus 2011 Healthcare Conference

MONTREAL--(BUSINESS WIRE)-- Angiochem, Inc., a clinical stage biotechnology company, today announced that Jean Paul Castaigne, MD, President and CEO is scheduled to present at the Stifel Nicolaus 2011 Healthcare Conference at 2:05 p.m. ET on Wednesday, September 7, 2011, at the Four Seasons Hotel, Boston.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and metabolic diseases, pain, and many others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit


Media Contact:
The Yates Network
Gina Nugent, 617-460-3579
Business Development Contact:
Angiochem, Inc.
Catherine Gagnon, 514-788-7800 x204

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Mental Health  Pharmaceutical  Other Health  Research  Science


Suggested Articles

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.

In our EuroBiotech roundup this week, Nordic Nanovector delays phase 2b readout, PPF buys big Autolus stake and Poxel shares phase 3 diabetes data.